Sandoz Group AG and Evotec SE Announce Potential Acquisition of Just-Evotec Biologics

On July 30, 2025, Sandoz Group AG, a leading pharmaceutical company based in Switzerland, announced a significant development in its strategic growth plans. The company has signed a non-binding term sheet with Evotec SE to acquire Just-Evotec Biologics, a biologics development and manufacturing facility located in Toulouse, France. This potential acquisition is part of Sandoz’s broader strategy to enhance its biosimilar development and manufacturing capabilities.

The proposed transaction aligns with Sandoz’s strategic objective of capitalizing on the projected USD 300 billion biosimilar market opportunity over the next decade. By acquiring Just-Evotec Biologics, Sandoz aims to reinforce its in-house biosimilar development and manufacturing capabilities, thereby creating additional strategic flexibility.

The deal involves the transfer of advanced continuous manufacturing technology from Evotec to Sandoz, which is expected to enable Sandoz to produce biosimilar medicines more efficiently. The transaction is valued at approximately US$ 300 million in cash, with additional technology-related considerations, including future development revenues, milestones, and product royalties.

This move is part of Evotec SE’s asset-light strategy, as the company seeks to streamline its operations and focus on its core competencies. The non-binding agreement marks a significant step in the evolving strategic partnership between Evotec and Sandoz.

Sandoz Group AG, listed on the SIX Swiss Exchange, has a market capitalization of CHF 23.66 billion. The company specializes in manufacturing and distributing generic and biosimilar medicines for various diseases, including cancer, diabetes, and arthritis, serving customers globally.

The acquisition of Just-Evotec Biologics is expected to provide Sandoz with a competitive edge in the rapidly growing biosimilar market, reinforcing its position as a leader in the pharmaceutical industry. Further details of the transaction are anticipated as the parties continue their discussions.

For more information about Sandoz Group AG and its products and services, visit their website at www.sandoz.com .